- Home
- TOVX vs XBIO Comparison
TOVX vs XBIO Comparison
Compare TOVX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- XBIO
- Stock Information
- Founded
- TOVX 2001
- XBIO N/A
- Country
- TOVX United States
- XBIO United States
- Employees
- TOVX N/A
- XBIO N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- XBIO Health Care
- Exchange
- TOVX Nasdaq
- XBIO Nasdaq
- Market Cap
- TOVX 3.8M
- XBIO 4.4M
- IPO Year
- TOVX 2006
- XBIO N/A
- Fundamental
- Price
- TOVX $0.42
- XBIO $4.21
- Analyst Decision
- TOVX Hold
- XBIO Hold
- Analyst Count
- TOVX 1
- XBIO 1
- Target Price
- TOVX N/A
- XBIO N/A
- AVG Volume (30 Days)
- TOVX 13.2M
- XBIO 2.5M
- Earning Date
- TOVX 11-11-2025
- XBIO 11-11-2025
- Dividend Yield
- TOVX N/A
- XBIO N/A
- EPS Growth
- TOVX N/A
- XBIO N/A
- EPS
- TOVX N/A
- XBIO N/A
- Revenue
- TOVX N/A
- XBIO $2,446,221.00
- Revenue This Year
- TOVX N/A
- XBIO $1.99
- Revenue Next Year
- TOVX N/A
- XBIO $20.00
- P/E Ratio
- TOVX N/A
- XBIO N/A
- Revenue Growth
- TOVX N/A
- XBIO N/A
- 52 Week Low
- TOVX $0.37
- XBIO $2.20
- 52 Week High
- TOVX $2.64
- XBIO $13.93
- Technical
- Relative Strength Index (RSI)
- TOVX 48.00
- XBIO 48.64
- Support Level
- TOVX $0.39
- XBIO $2.81
- Resistance Level
- TOVX $0.86
- XBIO $13.93
- Average True Range (ATR)
- TOVX 0.08
- XBIO 1.11
- MACD
- TOVX 0.01
- XBIO -0.11
- Stochastic Oscillator
- TOVX 6.71
- XBIO 12.59
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.